News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
-
Rhea-AI Summary
Elekta has received U.S. FDA 510(k) clearance for its Geneva Universal Gynecological Applicator, enabling enhanced brachytherapy treatment for cervical cancer patients in the U.S. This device is designed for cervical cancer up to stage IIB and can assist 75% of patients with locally advanced cases. Each year, there are 570,000 new cervical cancer diagnoses globally. Elekta's Geneva aims to support these patients by providing a versatile, easy-to-use applicator with multiple size options. The innovation aligns with established guidelines, enhancing treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
FAQ
What is the current stock price of Elekta (EKTAY)?
Elekta (EKTAY) last closed at $6.16.
What is the market cap of Elekta (EKTAY)?
The market cap of Elekta (EKTAY) is approximately $2.4B.